These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 29733614)

  • 1. Rational Design of Novel 1,3-Oxazine Based β-Secretase (BACE1) Inhibitors: Incorporation of a Double Bond To Reduce P-gp Efflux Leading to Robust Aβ Reduction in the Brain.
    Fuchino K; Mitsuoka Y; Masui M; Kurose N; Yoshida S; Komano K; Yamamoto T; Ogawa M; Unemura C; Hosono M; Ito H; Sakaguchi G; Ando S; Ohnishi S; Kido Y; Fukushima T; Miyajima H; Hiroyama S; Koyabu K; Dhuyvetter D; Borghys H; Gijsen HJM; Yamano Y; Iso Y; Kusakabe KI
    J Med Chem; 2018 Jun; 61(12):5122-5137. PubMed ID: 29733614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization of 1,4-Oxazine β-Secretase 1 (BACE1) Inhibitors Toward a Clinical Candidate.
    Gijsen HJM; Alonso de Diego SA; De Cleyn M; García-Molina A; Macdonald GJ; Martínez-Lamenca C; Oehlrich D; Prokopcova H; Rombouts FJR; Surkyn M; Trabanco AA; Van Brandt S; Van den Bossche D; Van Gool M; Austin N; Borghys H; Dhuyvetter D; Moechars D
    J Med Chem; 2018 Jun; 61(12):5292-5303. PubMed ID: 29809004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spirocyclic sulfamides as β-secretase 1 (BACE-1) inhibitors for the treatment of Alzheimer's disease: utilization of structure based drug design, WaterMap, and CNS penetration studies to identify centrally efficacious inhibitors.
    Brodney MA; Barreiro G; Ogilvie K; Hajos-Korcsok E; Murray J; Vajdos F; Ambroise C; Christoffersen C; Fisher K; Lanyon L; Liu J; Nolan CE; Withka JM; Borzilleri KA; Efremov I; Oborski CE; Varghese A; O'Neill BT
    J Med Chem; 2012 Nov; 55(21):9224-39. PubMed ID: 22984865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trifluoromethyl Dihydrothiazine-Based β-Secretase (BACE1) Inhibitors with Robust Central β-Amyloid Reduction and Minimal Covalent Binding Burden.
    Anan K; Iso Y; Oguma T; Nakahara K; Suzuki S; Yamamoto T; Matsuoka E; Ito H; Sakaguchi G; Ando S; Morimoto K; Kanegawa N; Kido Y; Kawachi T; Fukushima T; Teisman A; Urmaliya V; Dhuyvetter D; Borghys H; Austin N; Van Den Bergh A; Verboven P; Bischoff F; Gijsen HJM; Yamano Y; Kusakabe K
    ChemMedChem; 2019 Nov; 14(22):1894-1910. PubMed ID: 31657130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors with in vivo brain reduction of β-amyloid peptides.
    Swahn BM; Kolmodin K; Karlström S; von Berg S; Söderman P; Holenz J; Berg S; Lindström J; Sundström M; Turek D; Kihlström J; Slivo C; Andersson L; Pyring D; Rotticci D; Ohberg L; Kers A; Bogar K; von Kieseritzky F; Bergh M; Olsson LL; Janson J; Eketjäll S; Georgievska B; Jeppsson F; Fälting J
    J Med Chem; 2012 Nov; 55(21):9346-61. PubMed ID: 22924815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toward β-Secretase-1 Inhibitors with Improved Isoform Selectivity.
    Johansson P; Kaspersson K; Gurrell IK; Bäck E; Eketjäll S; Scott CW; Cebers G; Thorne P; McKenzie MJ; Beaton H; Davey P; Kolmodin K; Holenz J; Duggan ME; Budd Haeberlein S; Bürli RW
    J Med Chem; 2018 Apr; 61(8):3491-3502. PubMed ID: 29617572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice.
    Meredith JE; Thompson LA; Toyn JH; Marcin L; Barten DM; Marcinkeviciene J; Kopcho L; Kim Y; Lin A; Guss V; Burton C; Iben L; Polson C; Cantone J; Ford M; Drexler D; Fiedler T; Lentz KA; Grace JE; Kolb J; Corsa J; Pierdomenico M; Jones K; Olson RE; Macor JE; Albright CF
    J Pharmacol Exp Ther; 2008 Aug; 326(2):502-13. PubMed ID: 18499745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1,4-Oxazine β-Secretase 1 (BACE1) Inhibitors: From Hit Generation to Orally Bioavailable Brain Penetrant Leads.
    Rombouts FJ; Tresadern G; Delgado O; Martínez-Lamenca C; Van Gool M; García-Molina A; Alonso de Diego SA; Oehlrich D; Prokopcova H; Alonso JM; Austin N; Borghys H; Van Brandt S; Surkyn M; De Cleyn M; Vos A; Alexander R; Macdonald G; Moechars D; Gijsen H; Trabanco AA
    J Med Chem; 2015 Oct; 58(20):8216-35. PubMed ID: 26378740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utilizing structures of CYP2D6 and BACE1 complexes to reduce risk of drug-drug interactions with a novel series of centrally efficacious BACE1 inhibitors.
    Brodney MA; Beck EM; Butler CR; Barreiro G; Johnson EF; Riddell D; Parris K; Nolan CE; Fan Y; Atchison K; Gonzales C; Robshaw AE; Doran SD; Bundesmann MW; Buzon L; Dutra J; Henegar K; LaChapelle E; Hou X; Rogers BN; Pandit J; Lira R; Martinez-Alsina L; Mikochik P; Murray JC; Ogilvie K; Price L; Sakya SM; Yu A; Zhang Y; O'Neill BT
    J Med Chem; 2015 Apr; 58(7):3223-52. PubMed ID: 25781223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of Potent and Centrally Active 6-Substituted 5-Fluoro-1,3-dihydro-oxazine β-Secretase (BACE1) Inhibitors via Active Conformation Stabilization.
    Nakahara K; Fuchino K; Komano K; Asada N; Tadano G; Hasegawa T; Yamamoto T; Sako Y; Ogawa M; Unemura C; Hosono M; Ito H; Sakaguchi G; Ando S; Ohnishi S; Kido Y; Fukushima T; Dhuyvetter D; Borghys H; Gijsen HJM; Yamano Y; Iso Y; Kusakabe KI
    J Med Chem; 2018 Jul; 61(13):5525-5546. PubMed ID: 29775538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spirocyclic β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors: from hit to lowering of cerebrospinal fluid (CSF) amyloid β in a higher species.
    Hunt KW; Cook AW; Watts RJ; Clark CT; Vigers G; Smith D; Metcalf AT; Gunawardana IW; Burkard M; Cox AA; Geck Do MK; Dutcher D; Thomas AA; Rana S; Kallan NC; DeLisle RK; Rizzi JP; Regal K; Sammond D; Groneberg R; Siu M; Purkey H; Lyssikatos JP; Marlow A; Liu X; Tang TP
    J Med Chem; 2013 Apr; 56(8):3379-403. PubMed ID: 23537249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of gamma-secretase and BACE1 inhibition on brain Abeta levels in vitro and in vivo.
    Elvang AB; Volbracht C; Pedersen LØ; Jensen KG; Karlsson JJ; Larsen SA; Mørk A; Stensbøl TB; Bastlund JF
    J Neurochem; 2009 Sep; 110(5):1377-87. PubMed ID: 19519664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Balancing potency and basicity by incorporating fluoropyridine moieties: Discovery of a 1-amino-3,4-dihydro-2,6-naphthyridine BACE1 inhibitor that affords robust and sustained central Aβ reduction.
    Nakahara K; Mitsuoka Y; Kasuya S; Yamamoto T; Yamamoto S; Ito H; Kido Y; Kusakabe KI
    Eur J Med Chem; 2021 Apr; 216():113270. PubMed ID: 33765486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New aminoimidazoles as β-secretase (BACE-1) inhibitors showing amyloid-β (Aβ) lowering in brain.
    Gravenfors Y; Viklund J; Blid J; Ginman T; Karlström S; Kihlström J; Kolmodin K; Lindström J; von Berg S; von Kieseritzky F; Bogar K; Slivo C; Swahn BM; Olsson LL; Johansson P; Eketjäll S; Fälting J; Jeppsson F; Strömberg K; Janson J; Rahm F
    J Med Chem; 2012 Nov; 55(21):9297-311. PubMed ID: 23017051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining an amyloid-beta (Aβ) cleaving enzyme inhibitor with a γ-secretase modulator results in an additive reduction of Aβ production.
    Strömberg K; Eketjäll S; Georgievska B; Tunblad K; Eliason K; Olsson F; Radesäter AC; Klintenberg R; Arvidsson PI; von Berg S; Fälting J; Cowburn RF; Dabrowski M
    FEBS J; 2015 Jan; 282(1):65-73. PubMed ID: 25303711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of amino-1,4-oxazines as potent BACE-1 inhibitors.
    Veenstra SJ; Rueeger H; Voegtle M; Lueoend R; Holzer P; Hurth K; Tintelnot-Blomley M; Frederiksen M; Rondeau JM; Jacobson L; Staufenbiel M; Neumann U; Machauer R
    Bioorg Med Chem Lett; 2018 Jul; 28(12):2195-2200. PubMed ID: 29764741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishing the relationship between in vitro potency, pharmacokinetic, and pharmacodynamic parameters in a series of orally available, hydroxyethylamine-derived β-secretase inhibitors.
    Wood S; Wen PH; Zhang J; Zhu L; Luo Y; Babu-Khan S; Chen K; Pham R; Esmay J; Dineen TA; Kaller MR; Weiss MM; Hitchcock SA; Citron M; Zhong W; Hickman D; Williamson T
    J Pharmacol Exp Ther; 2012 Nov; 343(2):460-7. PubMed ID: 22911925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis of the Potent, Selective, and Efficacious β-Secretase (BACE1) Inhibitor NB-360.
    Rueeger H; Lueoend R; Machauer R; Veenstra SJ; Holzer P; Hurth K; Voegtle M; Frederiksen M; Rondeau JM; Tintelnot-Blomley M; Jacobson LH; Staufenbiel M; Laue G; Neumann U
    J Med Chem; 2021 Apr; 64(8):4677-4696. PubMed ID: 33844524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of potent, orally efficacious hydroxyethylamine derived β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors.
    Dineen TA; Weiss MM; Williamson T; Acton P; Babu-Khan S; Bartberger MD; Brown J; Chen K; Cheng Y; Citron M; Croghan MD; Dunn RT; Esmay J; Graceffa RF; Harried SS; Hickman D; Hitchcock SA; Horne DB; Huang H; Imbeah-Ampiah R; Judd T; Kaller MR; Kreiman CR; La DS; Li V; Lopez P; Louie S; Monenschein H; Nguyen TT; Pennington LD; San Miguel T; Sickmier EA; Vargas HM; Wahl RC; Wen PH; Whittington DA; Wood S; Xue Q; Yang BH; Patel VF; Zhong W
    J Med Chem; 2012 Nov; 55(21):9025-44. PubMed ID: 22468684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor.
    May PC; Dean RA; Lowe SL; Martenyi F; Sheehan SM; Boggs LN; Monk SA; Mathes BM; Mergott DJ; Watson BM; Stout SL; Timm DE; Smith Labell E; Gonzales CR; Nakano M; Jhee SS; Yen M; Ereshefsky L; Lindstrom TD; Calligaro DO; Cocke PJ; Greg Hall D; Friedrich S; Citron M; Audia JE
    J Neurosci; 2011 Nov; 31(46):16507-16. PubMed ID: 22090477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.